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OBJECTIVES We evaluated the effects of long-term therapy with the angiotensin-converting enzyme
(ACE) inhibitor ramipril on major cardiovascular (CV) outcomes in high-risk women.
BACKGROUND The effect of long-term ACE inhibitor therapy in high-risk women without heart failure and
with preserved left ventricular (LV) systolic function has not been previously reported.
METHODS The Heart Outcomes Prevention Evaluation (HOPE) trial is a large, randomized clinical trial
that evaluated ramipril and vitamin E in high-risk patients. We present the preplanned
analysis of the effects of ramipril in women in the HOPE study. The study randomized 2,480
women aged 55 years with vascular disease or diabetes and at least one additional CV risk
factor and without heart failure or a known low LV ejection fraction to ramipril (10 mg/day)
or placebo. The primary outcome was the composite of myocardial infarction, stroke or CV
death. Average follow-up was 4.5 years.
RESULTS Treatment with ramipril resulted in reduced primary end point rates (11.3% vs. 14.9% in the
placebo arm; relative risk [RR] 0.77, 95% confidence interval [CI] 0.62 to 0.96; p  0.019),
fewer strokes (3.1% vs. 4.8%; RR 0.64, 95% CI 0.43 to 0.96; p 0.029) and fewer CV deaths
(4.2% vs. 6.9%; RR 0.62, 95% CI 0.44 to 0.88; p  0.0068). There were trends toward
reduced rates of myocardial infarction, heart failure and all-cause death. The beneficial effect
of ramipril was similar in women and men.
CONCLUSIONS Treatment with ramipril reduces the CV risk in high-risk women without heart failure and
with preserved LV systolic function. (J Am Coll Cardiol 2002;40:693–702) © 2002 by the
American College of Cardiology Foundation
Ischemic cardiovascular disease (CVD) is the leading cause
of death and a significant cause of morbidity among women
in industrialized countries (1). Most cardiovascular (CV)
events occur in postmenopausal women. Given the in-
creasing life expectancy of women and the rise in the
prevalence of diabetes, hypertension and other risk fac-
tors in the elderly, it is expected that the burden of death
and disability related to CVD in women will increase
further. Therefore, it is important to identify preventive
strategies that can decrease the risk of a broad range of
CV events in women.
Women have been generally underrepresented in clinical
trials of CVD (2,3), and the evaluation of CV therapies in
women has been frequently based on subgroup analyses.
Results of such subgroup analyses are subject to numerous
potential sources of error (4). A major confusing issue has
been the frequent attempt to interpret subgroup data in
isolation, even in trials that included only relatively few
women; thus, there was a lack of adequate power for such
analyses.
Angiotensin-converting enzyme (ACE) inhibitors have
been clearly shown to have a wide range of cardiac and
vascular protective actions (5,6). Until recently, CV trials
had evaluated the long-term use of ACE inhibitors primar-
ily in patients with heart failure and/or asymptomatic left
ventricular (LV) dysfunction, and these trials had generally
enrolled relatively few women (7–11).
The Heart Outcomes Prevention Evaluation (HOPE)
study, a large, multi-center, randomized trial, evaluated the
effects of the ACE inhibitor ramipril and of vitamin E in
high-risk patients without heart failure and with preserved
LV function (12). The study specifically attempted to
recruit a large number of women to have reasonable power
to detect moderate and plausible differences separately in
this subgroup. This report focuses on analyses of the effects
of ramipril in the women enrolled in the HOPE trial.
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METHODS
The analysis of the effects of ramipril on major CV events in
the women enrolled in the HOPE trial was preplanned.
The Data Safety and Monitoring Committee, the Writing
Group and the Data Management and Statistical Centre for
this study were fully independent of the study sponsors.
Detailed descriptions of the HOPE study design have been
published (12,13). A brief summary with emphasis on
details relevant to the current report follows.
Study group. The HOPE trial enrolled women and men at
high risk of CV events. Patients were eligible if they were
55 years, had a history of CVD (coronary artery disease
[CAD], stroke or peripheral artery disease) or diabetes in
the presence of at least one additional CV risk factor (total
cholesterol5.2 mmol/l [200 mg/dl], high-density lipopro-
tein cholesterol 0.9 mmol/l [35 mg/dl], hypertension
[defined as the use of medication[s] to treat high blood
pressure or blood pressure 160 mm Hg systolic or 90
mm Hg diastolic at the time of recruitment], known
microalbuminuria or current smoking). Exclusion criteria
included history of congestive heart failure or a known low
LV ejection fraction (40%), uncontrolled hypertension,
myocardial infarction (MI), unstable angina or stroke within
one month before study enrollment, use of or intolerance to
ACE inhibitors or vitamin E and other major life-
threatening illnesses. We attempted to randomize a high
proportion (25% to 30%) of women. All study participants
provided written informed consent and the study protocol
was approved by the Research Ethics Board of each partic-
ipating center.
Study design. After an active run-in period on ramipril at
2.5 mg/day, study patients were randomized to ramipril
titrated up to 10 mg/day or placebo and to 400 IU/day
natural-source vitamin E (RRR-alpha-tocopherol acetate)
or placebo, using a 2  2 factorial study design.
Follow-up and study outcomes. After randomization, pa-
tients were evaluated at one month, six months and every six
months thereafter. At each visit, data were collected on
outcome events, compliance and side effects. At baseline,
one month, two years and study end, additional data were
obtained on the use of concomitant drugs, and blood
pressure was measured. Average follow-up was 4.5 years.
The primary study outcome was the composite of MI,
stroke or CV death. Each individual component of the
primary outcome was analyzed separately. The specified
secondary study outcomes were all-cause death, revascular-
ization procedures, hospital admission for unstable angina
or heart failure and complications related to diabetes. Other
outcomes analyzed were worsening angina, cardiac arrest,
heart failure (with or without hospital admission), unstable
angina with electrocardiographic changes and the develop-
ment of diabetes. Detailed definitions of these outcomes
have been published (13).
Statistical analysis. Statistical analyses were carried out
using SAS version 6.02 (SAS Institute, Cary, North Caro-
lina). We targeted the recruitment of 2,500 women and
predicted an annual primary event rate of 4% in the placebo
arm. For an average follow-up of five years, the planned
analysis of the effects of ramipril in women was anticipated
to have 80% power to detect a treatment effect of 25%.
The HOPE study was stopped early because of clear
Table 1. Baseline Characteristics of the HOPE Study Women
and Men
Characteristic
Women
(n  2,480)
Men
(n  6,817)
Age (yrs) 66.7  6.9 65.6  6.6†
Heart rate (beats/min) 71.5  11.1 67.7  11.2†
Systolic blood pressure (mm Hg) 142.5  20.7 137.3  19.1‡
Diastolic blood pressure (mm Hg) 78.8  11.1 78.9  10.4
Body mass index (kg/m2) 28.5  5.4 27.4  3.9†
History
Coronary artery disease 1,643 (66.3%) 5834 (85.6%)†
Myocardial infarction 929 (37.5%) 3963 (58.2%)†
Within 1 year 210 (8.5%) 688 (10.1%)§
Within 1 year 719 (29.0%) 3275 (48.0%)†
Stable angina 1,187 (47.9%) 3975 (58.1%)†
Unstable angina 564 (22.8%) 1803 (26.5%)‡
CABG 376 (15.2%) 2023 (29.7%)†
PTCA 378 (15.2%) 1281 (18.8%)†
Stroke or TIA 273 (11.0%) 740 (10.9%)
Peripheral artery disease* 1,226 (49.4%) 2825 (41.4%)†
Hypertension 1,496 (60.3%) 2859 (41.9%)†
Diabetes 1,322 (53.3%) 2255 (33.1%)†
Elevated total cholesterol
5.2 mmol/l
1,761 (71.0%) 4364 (64.0%)†
Low HDL cholesterol
0.9 mmol/l
321 (12.9%) 1402 (20.6%)†
Current cigarette smoking 347 (14.0%) 972 (14.3%)
Medications
Aspirin or other antiplatelet
drugs
1,580 (63.7%) 5494 (80.6%)†
Beta-blockers 848 (34.2%) 2825 (41.4%)†
Lipid-lowering agents 737 (29.7%) 1921 (28.2%)
Diuretics 616 (24.8)% 803 (11.8%)†
Calcium channel blockers 1,187 (47.9%) 3193 (46.8%)
LV hypertrophy on ECG 210 (13.6%) 575 (11.9%)
Microalbuminuria 601 (24.2%) 1362 (20.0%)†
Data are presented as the mean  SD or number (%) of subjects. *Peripheral artery
disease included a history of claudication, significant (50%) stenosis by angiography,
previous surgery or angioplasty or an ankle/arm blood pressure ratio 0.90; †p 
0.0001; ‡p  0.001; §p  0.05.
CABG  coronary artery bypass graft surgery; ECG  electrocardiogram;
HDL  high-density lipoprotein; HOPE  Heart Outcomes Prevention Evaluation
trial; LV left ventricular; PTCA percutaneous transluminal coronary angioplasty;
TIA  transient ischemic attack.
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AT1  angiotensin II type 1 receptor
CAD  coronary artery disease
CI  confidence interval
CV  cardiovascular
CVD  cardiovascular disease
HOPE  Heart Outcomes Prevention Evaluation trial
LV  left ventricle
MI  myocardial infarction
RR  relative risk
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evidence of a benefit with ramipril (12). Because this is a
subgroup analysis of the HOPE study, we first assessed the
balance in the baseline characteristics between women and
men, and we compared the overall outcomes, independent
of treatment assignment, between women and men. The t
test or chi-square test, as appropriate, was used to evaluate
the balance in the baseline characteristics, and Cox propor-
tional hazards models, unadjusted and adjusted for baseline
imbalances, were used to compare outcomes in women and
Table 2. Primary, Secondary and Other Outcomes in Women and Men
Women
(n  2,480)
Men
(n  6,817) RR (95% CI)*
Primary outcome
MI, stroke or CV death 324 (13.1%) 1,153 (16.9%) 1.34 (1.17–1.53)¶
MI 218 (8.8%) 811 (11.9%) 1.30 (1.11–1.53)
Stroke 98 (4.0%) 284 (4.2%) 1.25 (0.98–1.61)
CV death 137 (5.5%) 522 (7.7%) 1.50 (1.23–1.83)¶
Secondary outcomes
Noncardiovascular death 120 (4.8%) 272 (4.0%) 0.93 (0.74–1.18)
All-cause death 257 (10.4%) 794 (11.7%) 1.23 (1.06–1.43)
Revascularization† 323 (13.0%) 1,274 (18.7%) 1.36 (1.19–1.55)¶
Hospital admission for unstable angina 273 (11.0%) 848 (12.4%) 1.09 (0.95–1.22)
Hospital admission for heart failure 88 (3.6%) 214 (3.1%) 0.89 (0.55–1.16)
Other outcomes
Heart failure‡ 253 (10.2%) 698 (10.2%) 1.13 (0.97–1.33)
Cardiac arrest 17 (0.7%) 79 (1.2%) 1.44 (0.83–2.51)
Worsening angina 587 (23.7%) 1,742 (25.6%) 1.15 (1.06–1.23)
Unstable angina with ECG changes 91 (3.7%) 265 (3.9%) 1.12 (0.86–1.32)
New diagnosis of diabetes§ 43 (3.7%) 214 (4.7%) 1.48 (1.04–2.10)#
Diabetic complications 250 (10.1%) 409 (6.0%) 0.95 (0.80–1.13)
*Adjusted for baseline imbalances (Cox model); relative risk (RR) 1 indicates an increased risk in men; †includes coronary and
peripheral surgical and percutaneous revascularizations; ‡includes all diagnoses of heart failure with or without hospital admission
and deaths due to heart failure; §in patients without diabetes at baseline; ¶p 0.0001; p 0.01; #p 0.05. Data are presented
as the number (%) of events.
CI  confidence interval; CV  cardiovascular; ECG  echocardiographic; MI  myocardial infarction.
Table 3. Baseline Characteristics of Women in the Placebo and
Ramipril Groups
Characteristics
Placebo
(n  1,201)
Ramipril
(n  1,279)
Age (yrs) 66.7  6.8 66.8  7.1
Heart rate (beats/min) 71.6  10.8 71.5  11.5
Systolic blood pressure (mm Hg) 142.1  20.6 142.8  20.8
Diastolic blood pressure (mm Hg) 78.6  11.1 78.9  11.1
Body mass index (kg/m2) 28.7  5.5 28.6  5.3
History
Coronary artery disease 833 (69.4%) 810 (63.6%)*
Myocardial infarction 477 (39.8%) 452 (35.3%)
Within 1 year 104 (8.7%) 106 (8.3%)
Within 1 year 373 (31.1%) 346 (27.1%)†
Stable angina 596 (49.6%) 591 (46.3%)
Unstable angina 300 (25.0%) 264 (20.7%)†
CABG 199 (16.6%) 177 (13.8%)
PTCA 182 (15.2%) 196 (15.3%)
Stroke or TIA 143 (11.9%) 130 (10.2%)
Peripheral artery disease 592 (49.3%) 634 (49.6%)
Hypertension 724 (60.3%) 772 (60.4%)
Diabetes 626 (52.1%) 696 (54.4%)
Elevated total cholesterol 867 (72.2%) 894 (69.9%)
Low HDL cholesterol 146 (12.2%) 175 (13.7%)
Current cigarette smoking 171 (14.2%) 176 (13.8%)
Medications
Aspirin or other antiplatelet drugs 796 (66.3%) 784 (61.3%)*
Beta-blockers 433 (36.1%) 415 (32.5%)
Lipid-lowering agents 347 (28.9%) 390 (30.5%)
Diuretics 305 (25.4%) 311 (24.3%)
Calcium channel blockers 589 (49.0%) 598 (46.8%)
LV hypertrophy on ECG 104 (13.8%) 106 (13.4%)
Microalbuminuria 304 (26.0%) 297 (24.0%)
*p  0.01; †p  0.05. Data are presented as the mean  SD or number (%) of
subjects.
Abbreviations as in Table 1.
Table 4. Reasons for Discontinuation of Study Drug in the
HOPE Study Women
Placebo Group
(n  1,201)
Ramipril Group
(n  1,279)
Discontinuation at any time 457 (35.7%) 411 (34.2%)
Permanent discontinuation 406 (31.7%) 358 (29.8%)
Reasons for stopping*
Cough 26 (2.2%) 145 (11.3%)†
Hypotension or dizziness 22 (1.8%) 33 (2.6%)
Angioedema 1 (0.1%) 9 (0.7%)‡
Uncontrolled hypertension 65 (5.4%) 31 (2.4%)§
Clinical events 93 (7.7%) 78 (6.1%)
Other 320 (26.6%) 317 (24.8%)
Use of nonstudy ACE
inhibitor at any time
Reasons for use*
Heart failure 63 (5.3%) 53 (4.1%)
Proteinuria 17 (1.4%) 18 (1.4%)
Hypertension 105 (8.7%) 75 (5.9%)¶
Other 94 (7.8%) 88 (6.9%)
*The categories are not mutually exclusive; †p  0.0001; ‡p  0.05; §p  0.001;
¶p  0.01. Data are presented as the number (%) of subjects.
ACE  angiotensin-converting enzyme; HOPE  Heart Outcomes Prevention
Evaluation trial.
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men. We then compared baseline characteristics in women
in the ramipril and placebo groups and analyzed the effect of
ramipril in women. All analyses of the effects of ramipril
were done on an intention-to-treat basis. Cox proportional
hazards models were fitted to examine the effect of ramipril
on study outcomes. Observed slight imbalances in baseline
characteristics between the placebo and ramipril groups
were controlled by fitting multivariate Cox models. Be-
cause of the factorial design, all analyses of the effects of
ramipril were stratified for randomization to vitamin E or
placebo. The effect of ramipril in women versus men was
compared using models with a ramipril– gender interac-
tion term and confirmed using the Breslow-Day test for
homogeneity of odds ratios. Subgroup analyses were
conducted to evaluate the consistency of the effect of
ramipril on the primary study outcome among predefined
subsets of women. Kaplan-Meier curves were drawn to
visually show the impact of treatment on the main study
outcomes.
RESULTS
The HOPE trial enrolled 2,545 women. Of these, 65 were
randomized to a lower dose of ramipril (2.5 mg/day or
placebo) as part of a substudy (14). Therefore, the main
analysis of the ACE inhibitor effect in women is described
for 2,480 patients. Inclusion of the additional 65 women
randomized to the lower ramipril dose or placebo did not
alter the study results.
Baseline characteristics and outcomes in women and
men. At baseline, women were slightly older than men, had
a higher systolic blood pressure and body mass index and
were more likely to have a history of peripheral artery
disease, hypertension, diabetes and hypercholesterolemia
(Table 1). Men were more likely to have a history of CAD,
previous MI, stable and unstable angina and previous
revascularization procedures. Men had worse outcomes than
women, both in the unadjusted analysis and after adjusting
for baseline differences (Table 2).
Table 5. Blood Pressure at Baseline and at Follow-Up in the HOPE Study Women
Baseline 1 Month 2 Years Study End
Systolic blood pressure (mm Hg)
Placebo group 142.1  20.6 140.4  19.9 141.5  19.5 142.1  20.6
Ramipril group 142.8  20.8 137.5  19.9 140.0  21.0 140.5  19.6
Diastolic blood pressure (mm Hg)
Placebo group 78.7  10.9 78.4  11.4 77.6  10.6 76.8  10.9
Ramipril group 78.9  11.1 76.6  10.9 76.6  11.4 76.2  10.9
Data are presented as the mean value  SD.
Table 6. Effect of Ramipril on Primary, Secondary and Other Study Outcomes in Women and Men
Women Men
p Value for
Interaction†
Placebo
Group
(n  1,201)
Ramipril
Group
(n  1,279) RR (95% CI)*
Placebo
Group
(n  3,451)
Ramipril
Group
(n  3,366) RR (95% CI)
Primary outcome
MI, stroke or CV death 179 (14.9%) 145 (11.3%) 0.77 (0.62–0.96)‡ 647 (18.8%) 506 (15.0%) 0.78 (0.70–0.88)¶ 0.95
MI 113 (9.4%) 105 (8.2%) 0.89 (0.69–1.17) 457 (13.2%) 354 (10.5%) 0.78 (0.68–0.90) 0.39
Stroke 58 (4.8%) 40 (3.1%) 0.64 (0.43–0.96)‡ 168 (4.9%) 116 (3.5%) 0.70 (0.55–0.88)§ 0.81
CV death 83 (6.9%) 54 (4.2%) 0.62 (0.44–0.88)§ 294 (8.5%) 228 (6.8%) 0.79 (0.66–0.94)§ 0.16
Secondary outcomes
All-cause death 139 (11.7%) 118 (9.2%) 0.80 (0.63–1.03) 430 (12.5%) 364 (10.8%) 0.86 (0.75–0.99)‡ 0.47
Revascularization 173 (14.4%) 150 (11.7%) 0.85 (0.68–1.06) 681 (19.7%) 593 (17.6%) 0.87 (0.78–0.97)‡ 0.70
Hospital admission for unstable angina 140 (11.7%) 133 (10.4%) 1.00 (0.80–1.29) 427 (12.4%) 421 (12.5%) 1.00 (0.88–1.15) 0.91
Hospitalization for heart failure 46 (3.8%) 42 (3.3%) 0.88 (0.58–1.34) 115 (3.3%) 99 (2.9%) 0.87 (0.67–1.14) 0.99
Other outcomes
All heart failure 136 (11.3%) 117 (9.2%) 0.81 (0.65–1.07) 398 (11.5%) 300 (8.9%) 0.75 (0.65–0.88) 0.49
Cardiac arrest 12 (1.0%) 5 (0.4%) 0.39 (0.14–1.11) 47 (1.4%) 32 (1.0%) 0.69 (0.44–1.07) 0.37
Worsening angina 312 (26.0%) 275 (21.5%) 0.88 (0.74–0.94)‡ 910 (26.4%) 832 (24.7%) 0.92 (0.84–1.01) 0.41
Unstable angina with ECG changes 41 (3.4%) 50 (3.9%) 1.30 (0.86–1.97) 140 (4.1%) 125 (3.7%) 0.91 (0.71–1.15) 0.18
New diagnosis of diabetes 27 (4.7%) 16 (2.7%) 0.57 (0.31–1.07) 128 (5.6%) 86 (3.8%) 0.68 (0.51–0.89)§ 0.67
Diabetic complications 124 (10.3%) 126 (9.9%) 0.98 (0.76–1.25) 232 (6.7%) 177 (5.3%) 0.77 (0.64–0.94)‡ 0.24
Data are provided as the number (%) of events. *Stratified for vitamin E and controlling for baseline imbalances between the placebo and the ramipril groups; †refers to the
comparison of the effects of ramipril in women vs. men—the p value is for the ramipril/gender interaction term in the Cox proportional hazards model stratified for vitamin E
and controlling for baseline imbalances between women and men and other predictors of risk. Similar lack differences for the effects of ramipril in women and in men for any
study outcomes were obtained in the unadjusted Cox model and when using the Breslow-Day test for homogeneity of odds ratios; ‡p  0.05; §p  0.01; p  0.001; ¶p 
0.0001.
RR  relative risk; other abbreviations in Table 2.
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Baseline characteristics and compliance of the HOPE
study women by treatment assignment. The baseline
characteristics of the 2,480 women in the placebo and
ramipril groups are shown in Table 3. Among the women
randomly assigned to the ramipril group, 83.7% were taking
ramipril at one year, 78.1% at two years, 76.6% at three
years, 75.6% at four years and 73.8% at the study end.
Among the women taking ramipril, the percentages of those
who were receiving the full dose of 10 mg/day were 81.3%
at one year, 68.6% at two years, 64.6% at three years, 55%
at four years and 59.8% at the study end. Among the women
who were randomly assigned to receive placebo, 88.8% were
taking it at one year, 78.9% at two years, 74.6% at three
years, 70.5% at four years and 68.1% at the end of the study.
In addition, among women randomized to receive placebo,
3.4% were taking an open-label ACE inhibitor at one year,
6.8% at two years, 9.1% at three years, 11.1% at four years
and 11.9% at the study end. Among causes for permanent
study drug discontinuation, cough and angioedema were
more common in women in the ramipril group and uncon-
trolled hypertension in those in the placebo group (Table 4).
Women in the placebo group were more likely to use a
nonstudy ACE inhibitor for blood pressure control (Table
4). More women than men required permanent discontin-
uation of active ramipril therapy because of cough (11.3% of
women in the ramipril group vs. 2.2% of women in the
placebo group, compared with 5.7% of men in the ramipril
group vs. 1.7% of men in the placebo group).
Blood pressure. Baseline and subsequent blood pressure
measurements in the HOPE study women are shown in
Table 5. The mean systolic and diastolic blood pressure
change over the duration of the study was 0.6  15.7 and
0.9  8.6 mm Hg in the placebo group and 3.6  16.5
and 2.4  9.1 mm Hg in the ramipril group, respectively.
Outcomes by treatment assignment. The primary, sec-
ondary and other outcomes by treatment assignment to
ramipril versus placebo are summarized in Table 6 and
Figure 1. The women in the ramipril arm of the study had
significantly fewer primary outcome events, deaths from CV
causes, strokes and episodes of worsening angina. The
beneficial effect of ramipril remained statistically signif-
icant after adjusting for the observed slight baseline
imbalances between the women in the two treatment
arms (no baseline imbalances between the treatment arms
were noted in men). A strong trend toward a reduction in
the risk of all-cause death was also noted; a total of 118
women (9.2%) in the ramipril group died, compared with
139 women (11.6%) in the placebo group (p [adjusted] 
0.08). There were also trends toward a reduced risk of
MI, revascularization, heart failure, cardiac arrest and a
new diagnosis of diabetes.
Comparison of ramipril effects in women versus men.
There were no statistically significant differences in the
effect of ramipril on any of the primary, secondary or other
study outcomes in women versus men, both in the unad-
justed analysis and after adjusting for baseline imbalances
and other predictors of risk (Table 6).
Subgroup analysis. The consistency of the results in key,
clinically relevant predefined subgroups of women is shown
in Figure 2. Although some subgroups had relatively few
patients and few outcomes of interest, there were statisti-
cally significant benefits or trends toward beneficial effects of
ramipril in all subgroups analyzed.
DISCUSSION
Treatment with ramipril significantly reduced the risk of
major vascular events in women. There was a 23% reduction
in the risk of nonfatal MI, stroke or CV death, a 38%
reduction in the risk of CV death and a 36% reduction in
the risk of stroke. The risk of worsening angina was also
significantly reduced. Similar trends were noted for other
CV outcomes, including MI, total mortality and the devel-
opment of heart failure. The beneficial effect of ACE
inhibitor therapy occurred in a wide range of middle-aged
and elderly postmenopausal women with a high prevalence
of risk factors, including a history of hypertension present in
60.3% at baseline, diabetes in 53.3%, hypercholesterolemia
in 71% and current smoking in 14%, and most of whom had
a history of vascular disease. The benefits noted were
additive to other medications with known cardioprotective
effects and/or known to favorably modify coronary risk
factors; these medications included beta-blockers adminis-
tered at baseline in 34% of women in the HOPE trial,
aspirin or other antiplatelet drugs in 64%, cholesterol-
lowering drugs in 30% (this increased to 50% by the study
end), diuretics in 25% and calcium channel blockers in 48%.
Similar to the overall HOPE study results, the magnitude
of the benefit on major clinical outcomes in women ap-
peared to exceed the small reduction in blood pressure
attained (3 mm Hg systolic/1.5 mm Hg diastolic) and is
likely to be related to a wide range of cardiac and vascular
protective actions of long-term ACE inhibitor therapy, in
addition to blood pressure lowering (5,6).
Previous clinical trials of long-term ACE inhibitor ther-
apy have been conducted in women and men with hyper-
tension and/or a low LV ejection fraction, with or without
previous MI and with or without heart failure. Based on
subgroup analyses in some of these trials, such as the
Survival And Ventricular Enlargement (SAVE) study,
which enrolled only 390 women, it was suggested that ACE
inhibitors may be less effective in women than in men
(15,16). In our study, we found no heterogeneity of effects
by gender. The effects of ramipril appeared to be similar in
women and in men, and this lack of gender-based difference
was noted after controlling for baseline differences and other
predictors of risk between women and men. We therefore
believe that previous suggestions of possible lesser efficacy of
ACE inhibitors in women are related to the low power of
subgroup analyses in studies that included only a small
number of women. A meta-analysis of the long-term ACE
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Figure 1. Kaplan-Meier estimates for the major cardiovascular (CV) outcomes and all-cause death in women and men in the ramipril and placebo
groups.
698 Lonn et al. JACC Vol. 40, No. 4, 2002
Ramipril in High-Risk Women August 21, 2002:693–702
Figure 1. Continued on next page.
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inhibitor trials in patients with a low ejection fraction also
suggests no significant heterogeneity of effects by gender
(17).
In our study, we noted an overall worse prognosis in
men versus women, and we believe that this is related to
the baseline differences in our study group, which in-
cluded fewer women with a history of CAD and a history
of MI.
Experimental studies have shown that estrogen defi-
ciency is associated with increased angiotensin II type 1
(AT1) receptor gene expression, leading to enhanced
biologic effects of the renin-angiotensin system, and it
was suggested that this may partly explain the increased
CV risk in postmenopausal women (18). Some, but not
all, experimental studies have shown that estrogen causes
downregulation of the vascular AT1 receptor and thus
may lead to decreased oxidative stress, improved endo-
thelial function and decreased CV risk (18 –20). Estrogen
administration in postmenopausal women may also re-
duce circulating ACE levels and suppress renin (21,22).
However, estrogen was also shown to increase angioten-
sin II levels (23). Based on the complex interaction
between estrogen and the renin-angiotensin system, a
potentially differential effect of ACE inhibitors in post-
menopausal women on estrogen replacement therapy
versus those not receiving estrogen has been suggested
(22). In our study, ramipril benefited both postmeno-
pausal women receiving and those not receiving hormone
replacement therapy. However, the number of women
receiving hormone replacement therapy was small, and
results of this subgroup analysis have to be regarded as
purely exploratory.
Conclusions. Our study provides strong evidence for the
role of ACE inhibitor therapy in postmenopausal women at
high risk of CV events, including those with established
coronary, cerebrovascular or peripheral arterial disease and
with diabetes and additional CV risk factors. This therapy
significantly reduced the risk of major vascular events, CV
death, stroke and worsening angina; the benefits were noted
in addition to other protective agents, such as antiplatelet
agents, beta-blockers and lipid-lowering drugs. The mag-
nitude of benefit attained with long-term ACE inhibitor
therapy in this middle-aged and elderly population at high
risk of CV events appears to be similar in women and in
men. Therefore, high-risk postmenopausal women should
consistently be treated with ACE inhibitors, and this
recommendation needs to be widely incorporated into
clinical guidelines.
Figure 1. Continued from previous page.
700 Lonn et al. JACC Vol. 40, No. 4, 2002
Ramipril in High-Risk Women August 21, 2002:693–702
Reprint requests and correspondence: Dr. Eva Lonn, Hamilton
Health Sciences, General Site, 237 Barton Street East, Hamilton,
Ontario, Canada L8L 2X2. E-mail: lonnem@mcmaster.ca.
REFERENCES
1. American Heart Association Inc. 1998 Heart and Stroke Facts:
Statistical Update. Dallas: American Heart Association, 1998.
2. Gurwitz JH, Nananda F, Avorn J. The exclusion of the elderly and
women from clinical trials in acute myocardial infarction. JAMA
1992;268:1417–22.
3. Harris DJ, Douglas PS. Enrollment of women in cardiovascular
clinical trials funded by the National Heart, Lung, and Blood Institute.
N Engl J Med 2000;343:476–80.
4. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpre-
tation of treatment effects in subgroups of patients in randomized
clinical trials. JAMA 1991;266:93–8.
5. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-
converting enzyme inhibitors in cardiac and vascular protection.
Circulation 1994;90:2056–69.
6. Dzau VJ. Mechanisms of protective effects of ACE inhibition on
coronary artery disease. Eur Heart J 1998;19 Suppl J:J2–6.
7. Pfeffer MA, Braunwald E, Moye´ LA, et al. Effect of captopril on
mortality and morbidity in patients with left ventricular dysfunction
after myocardial infarction: results of the Survival And Ventricular
Enlargement (SAVE) trial. N Engl J Med 1992;217:669–77.
8. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.
Effects of ramipril on mortality and morbidity of survivors of acute
myocardial infarction with clinical evidence of heart failure. Lancet
1993;342:821–8.
9. Kober L, Torp-Petersen C, Carlsen JE, et al., for the TRAndolapril
Cardiac Evaluation (TRACE) Study Group. A clinical trial of the
angiotensin-converting-enzyme inhibitor trandolapril in patients with
left ventricular dysfunction after myocardial infarction. N Engl J Med
1995;333:1670–6.
Figure 2. The effects of ramipril on the primary study outcome in key subgroups of women. The data show the consistency of the benefit of ramipril. The
dotted line represents the average treatment effect in women. The size of each box is proportional to the number of patients in each individual analysis.
The p value is for the subgroup–ramipril interaction term in the Cox proportional hazards model. Similar results were obtained using the test for
homogeneity of odds ratios in subgroups. CAD  coronary artery disease; CVD  cardiovascular disease; DM  diabetes mellitus; HRT  hormone
replacement therapy; MI  myocardial infarction; PAD  peripheral arterial disease; RR  relative risk; TIA  transient ischemic attack.
701JACC Vol. 40, No. 4, 2002 Lonn et al.
August 21, 2002:693–702 Ramipril in High-Risk Women
10. The SOLVD Investigators. Effect of enalapril on survival in patients
with reduced left ventricular ejection fractions and congestive heart
failure. N Engl J Med 1991;325:293–302.
11. The SOLVD Investigators. Effect of enalapril on mortality and the
development of heart failure in asymptomatic patients with reduced
left ventricular ejection fractions. N Engl J Med 1992;30:55–61.
12. The Heart Outcomes Prevention Evaluation Study Investigators.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on car-
diovascular events in high-risk patients. N Engl J Med 2000;342:145–53.
13. The Heart Outcomes Prevention Evaluation Study Investigators.
Vitamin E supplementation and cardiovascular events in high-risk
patients. N Engl J Med 2000;342:154–60.
14. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin
E on atherosclerosis: the Study to Evaluate Carotid Ultrasound
changes with Ramipril and vitamin E (SECURE). Circulation 2001;
103:919–25.
15. Lorell BH. ACE inhibitors after myocardial infarction (letter to the
editor). N Engl J Med 1993;328:966–7.
16. Klein W. Gender differences in clinical trials in coronary heart disease:
response to drug therapy. Eur Heart J 1996;17:1786–90.
17. Flather MD, Yusuf S, Kober L, et al., the ACE-Inhibitor Myo-
cardial Infarction Collaborative Group. Long-term ACE-inhibitor
therapy in patients with heart failure or left-ventricular dysfunction:
a systematic overview of data from individual patients. Lancet
2000;355:1575–81.
18. Nickening G, Ba¨umer AT, Grohe´ C, et al. Estrogen modulates AT1
receptor gene expression in vitro and in vivo. Circulation 1998;97:
2197–201.
19. Nickening G, Strehlow K, Wassmann S, et al. Differential effects of
estrogen and progesterone on AT1 receptor expression in vascular
smooth muscle cells. Circulation 2000;102:1828–33.
20. Wassman S, Ba¨umer AT, Strehlow K, et al. Endothelial dysfunction
and oxidative stress during estrogen deficiency in spontaneously
hypertensive rats. Circulation 2001;103:435–41.
21. Nogawa N, Sumino H, Ichikawa S, et al. Effect of long-term hormone
replacement on angiotensin-converting enzyme activity and bradykinin in
postmenopausal women with essential hypertension and normotensive
postmenopausal women. Menopause 2001;8:210–5.
22. Schunkert H, Danser AHJ, Hense HW, et al. Effects of estrogen
replacement therapy on the renin-angiotensin system in postmeno-
pausal women. Circulation 1997;95:39–45.
23. Kang AK, Duncan JA, Cattran C, et al. Effect of oral contraceptives
on the renin angiotensin system and renal function. Am J Integrative
Physiol 2001;280:R807–13.
702 Lonn et al. JACC Vol. 40, No. 4, 2002
Ramipril in High-Risk Women August 21, 2002:693–702
